Zynerba Sketches Phase III Plan For Cannabinoid Gel In Fragile X
Positive Phase II study of cannabinoid ZYN002 sends stock soaring, but the trial was very small with an open-label design, and response was mostly recorded by caregivers.
You may also be interested in...
Zynerba's gel formulation of cannabidiol has failed to hit the primary endpoint in a second Phase II study in as many weeks, but the company maintains that there is a way forward.
Zynerba’s gel formulation of cannabidiol has disappointed in top-line data from a Phase II study in epilepsy patients with focal seizures, but some signals of efficacy in a companion study, and expected data from studies in two other indications, might influence future development plans.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.